<?xml version='1.0' encoding='utf-8'?>
<document id="31820128"><sentence text="Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea." /><sentence text="We analyzed the prevalence and severity of potential drug-drug interactions (PDDIs) in Korean patients receiving oral anticancer agents (OAAs) during two different periods" /><sentence text="" /><sentence text="A cross-sectional study was conducted using the national insurance reimbursement database" /><sentence text=" The subjects were adult outpatients diagnosed with cancer and prescribed OAAs at least once in 2010 or 2014" /><sentence text=" PDDIs were identified using a database and the PDDI severity was categorized as category X (contraindications) or D (consideration of therapy modification)" /><sentence text=" The associated factors for the occurrence of PDDIs were also analyzed" /><sentence text="" /><sentence text="Among the 118,258 patients prescribed OAAs in 2014, approximately 59% were middle-aged, and approximately half were diagnosed with breast cancer" /><sentence text=" The number of comorbidities increased over time, and majority were diagnosed with gastrointestinal disorders, hyperlipidemia, and psychonervous disorders" /><sentence text=" The PDDIs due to protein kinase inhibitors (PKIs) with gastrointestinal/metabolic and neurological drugs increased 3" /><sentence text="1- and 4" /><sentence text="9-fold, respectively, over the 5Â years, and 24" /><sentence text="0% of the PDDIs fell into category X" /><sentence text=" Tamoxifen, the most commonly prescribed OAAs, caused the PDDIs with antidepressants through QTc prolongation or pharmacokinetic interaction"><entity charOffset="1-10" id="DDI-PubMed.31820128.s15.e0" text="Tamoxifen" /></sentence><sentence text=" The PKIs prescription, cancer type like breast or hematologic cancer, and number of comorbidities or co-prescribing drugs were independently associated with the occurrence of PDDIs" /><sentence text="" /><sentence text="The risk of PDDIs in patients receiving OAAs increases, particularly with the concomitant use of PKIs with gastrointestinal or psychiatric drugs and endocrine agents with antidepressants" /><sentence text=" Considering the potential risk of chronic concomitant use of these drug classes in outpatients, healthcare professionals should be made aware of the potential interactions" /><sentence text="" /></document>